Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aten Porus Lifesciences
DescriptionMRI contrast agent
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentDiscovery
Standard IndicationRadiologic imaging
Indication DetailsMRI contrast agent to evaluate patients with compromised renal function or contraindicated with nephrogenic systemic fibrosis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today